Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

The present invention relates to polyfunctional organic dendritic molecules derived from alkyl phosphonates or esters, to a process for preparing the same and to the use thereof, in particular as drug carriers or contrast agents.

Provided herein are organophosphorous compounds useful as inhibitors of esterase proteins and in treating esterase-related diseases.

The present specification relates to an organic light emitting device, a method for manufacturing the same, and a composition for an organic material layer.

The present disclosure provides a phosphorus-containing compound represented by Formula (1), a resin composition comprising the phosphorus-containing compound, and an article made from the resin composition. The phosphorus-containing compound can achieve halogen-free flame retardancy while satisfying the requirements of excellent dielectricity, high copper foil peeling strength, high glass transition temperature, low percent thermal expansion and excellent heat resistance after moisture absorption. The resin composition comprises the following components or a prepolymer thereof: (A) 100 parts by weight of an unsaturated CC double bond-containing polyphenylene ether resin; and (B) 15 parts by weight to 90 parts by weight of the phosphorus-containing compound represented by Formula (1); wherein the prepolymer is obtained from a mixture through prepolymerization, and the mixture comprises at least the component (A) and the component (B). ##STR00001##